Dicerna CEO fears insider trading crackdown, withdraws own shares from Novo Nordisk offer
Douglas Fambrough, co-founder and current CEO of Dicerna, which recently received a USD 3.3bn acquisition offer by Novo Nordisk, no longer intends to offer his own shares as a part of the deal, fearing an insider trading crackdown.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Novo Nordisk's cash tender offer to acquire all outstanding Dicerna shares no longer includes CEO Douglas Fambrough's personal shares, according to documents amending the original filing to the US Securities and Exchange Commission (SEC).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
